Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.
$CGON
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $60.00 | Buy | UBS |
| 9/23/2024 | $66.00 | Outperform | RBC Capital Mkts |
| 8/28/2024 | $65.00 | Buy | ROTH MKM |
| 6/28/2024 | $65.00 | Buy | BofA Securities |
| 2/20/2024 | $75.00 | Overweight | Cantor Fitzgerald |
| 2/20/2024 | $42.00 | Neutral | Goldman |
| 2/20/2024 | $55.00 | Overweight | Morgan Stanley |
144 - CG Oncology, Inc. (0001991792) (Subject)
144 - CG Oncology, Inc. (0001991792) (Subject)
10-Q - CG Oncology, Inc. (0001991792) (Filer)
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202
UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00
RBC Capital Mkts initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $66.00
ROTH MKM initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G - CG Oncology, Inc. (0001991792) (Subject)
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monotherapy BOND-003 study – – Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing – IRVINE, Calif., Aug. 08, 2024 (GLOBE NE
IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP and enrollment in the study is ongoing. "Bladder cancer is a highly recurrent disease with few treatment options a
4/A - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
9 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 5 2 0 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated CG Oncology and provided 12-month price targets. The average target is $68.33, accompanied by a high estimate of $75.00 and a low estimate of $50.00. This current
B of A Securities analyst Charlie Yang initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $65.